Innoviva (INVA) Projected to Post Quarterly Earnings on Wednesday

Innoviva (NASDAQ:INVA) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $101.5680 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $1.60. The company had revenue of $114.61 million during the quarter, compared to the consensus estimate of $102.62 million. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. On average, analysts expect Innoviva to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Stock Performance

NASDAQ INVA opened at $22.99 on Tuesday. The firm’s 50 day simple moving average is $23.01 and its 200 day simple moving average is $21.21. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 7.54 and a beta of 0.38. The company has a current ratio of 14.64, a quick ratio of 13.85 and a debt-to-equity ratio of 0.22. Innoviva has a 1 year low of $16.52 and a 1 year high of $25.15.

Hedge Funds Weigh In On Innoviva

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning lifted its stake in Innoviva by 0.8% in the 3rd quarter. Creative Planning now owns 61,365 shares of the biotechnology company’s stock valued at $1,120,000 after purchasing an additional 461 shares during the last quarter. Verition Fund Management LLC grew its stake in shares of Innoviva by 0.3% during the third quarter. Verition Fund Management LLC now owns 175,855 shares of the biotechnology company’s stock worth $3,209,000 after buying an additional 527 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Innoviva by 3.8% during the fourth quarter. Bank of Montreal Can now owns 14,742 shares of the biotechnology company’s stock worth $295,000 after buying an additional 540 shares in the last quarter. Vise Technologies Inc. increased its holdings in shares of Innoviva by 6.1% during the third quarter. Vise Technologies Inc. now owns 12,581 shares of the biotechnology company’s stock worth $230,000 after buying an additional 724 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Innoviva by 4.2% in the 4th quarter. Quadrant Capital Group LLC now owns 23,513 shares of the biotechnology company’s stock valued at $470,000 after acquiring an additional 938 shares during the last quarter. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on INVA. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a report on Friday, March 27th. BTIG Research reissued a “buy” rating and set a $35.00 price target on shares of Innoviva in a report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.80.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.